<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>At Huddinge Hospital 275 patients underwent allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Among children in first remission of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> phase <z:mp ids='MP_0005481'>CML</z:mp> (early <z:hpo ids='HP_0001909'>leukemia</z:hpo>), with HLA-identical marrow the 8-year <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival was 77% </plain></SENT>
<SENT sid="2" pm="."><plain>This was better than 38% in children undergoing transplantation in second to fourth remission (p less than 0.0009) </plain></SENT>
<SENT sid="3" pm="."><plain>In adults with early <z:hpo ids='HP_0001909'>leukemia</z:hpo>, the 8-year <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival was 47% compared to 21% for intermediate-risk adults (p = 0.007) </plain></SENT>
<SENT sid="4" pm="."><plain>Among 25 patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> receiving marrow from HLA-identical siblings, the actuarial 10-year survival was 78% </plain></SENT>
<SENT sid="5" pm="."><plain>In 14 patients with various <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e>, of whom half received marrow from HLA-mismatched donors, the actuarial 7-year survival was 71% </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-three patients were given marrow from HLA-mismatched donors and had an increased incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GvHD) and <z:hpo ids='HP_0011420'>death</z:hpo> due to GvHD compared to recipients of HLA-identical bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>The major causes of <z:hpo ids='HP_0011420'>death</z:hpo> among our patients were relapse of <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0011420'>death</z:hpo> due to GvHD, cytomegalovirus (CMV) <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e>, <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>By preventing GvHD with T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> or <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) combined with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CsA) <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD decreased, but the incidence of relapse increased compared to patients treated with MTX or CsA alone </plain></SENT>
<SENT sid="9" pm="."><plain>This resulted in improved survival in patients older than 30 years, but a nonsignificant decrease in <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival in younger patients </plain></SENT>
<SENT sid="10" pm="."><plain>There was an association between <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus immunity in the recipient and GvHD </plain></SENT>
<SENT sid="11" pm="."><plain>CMV <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e> increased following GvHD and decreased in patients treated with MTX combined with CsA </plain></SENT>
<SENT sid="12" pm="."><plain>Invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> may be treated or prevented using <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> encapsulated in liposomes with few side effects </plain></SENT>
</text></document>